Molecular subtypes as potential biomarkers in renal cell carcinoma

Chadi Hage Chehade; Neeraj Agarwal

doi:10.1016/j.ccell.2024.04.003

Molecular subtypes as potential biomarkers in renal cell carcinoma

Cancer Cell. 2024 May 13;42(5):736-738. doi: 10.1016/j.ccell.2024.04.003. Epub 2024 Apr 25.

Authors

Chadi Hage Chehade¹, Neeraj Agarwal²

Affiliations

¹ Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
² Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: neeraj.agarwal@hci.utah.edu.

PMID: 38670092
DOI: 10.1016/j.ccell.2024.04.003

Abstract

The increasing number of approved treatment combinations for metastatic renal cell carcinoma highlights the need for actionable biomarkers to guide treatment selection. In this issue of Cancer Cell, Saliby et al. validate the distinct clinico-genomic profiles of expression-based molecular clusters identified in the IMmotion151 trial in the JAVELIN Renal 101 dataset.

MeSH terms

Biomarkers, Tumor* / genetics
Biomarkers, Tumor* / metabolism
Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / genetics
Carcinoma, Renal Cell* / metabolism
Carcinoma, Renal Cell* / pathology
Gene Expression Regulation, Neoplastic
Humans
Kidney Neoplasms* / genetics
Kidney Neoplasms* / metabolism
Kidney Neoplasms* / pathology